Plasma Protease C1-Inhibitor Market Report 2026

The plasma protease c1-inhibitor market size has grown rapidly in recent years. It will grow from $3.85 billion in 2025 to $4.4 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to increased diagnosis of hereditary angioedema, availability of plasma-derived inhibitors, improvements in plasma fractionation processes, expansion of specialty immunology clinics, improved patient access to targeted therapies.

The plasma protease c1-inhibitor market size is expected to see rapid growth in the next few years. It will grow to $7.44 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to increasing development of next-generation inhibitors, rising demand for self-administered therapies, expansion of rare disease treatment programs, growing investment in recombinant biologics, increasing focus on long-term disease control. Major trends in the forecast period include increasing adoption of recombinant c1-inhibitors, rising demand for plasma-derived therapies, growing focus on rare disease management, expansion of subcutaneous administration options, enhanced emphasis on treatment safety and efficacy.

The growing investment in rare diseases is expected to drive the growth of the plasma protease C1-inhibitor market going forward. Rare diseases are health conditions that affect a small portion of the population, typically fewer than 1 in 2,000 individuals. These conditions are often chronic, progressive, and can be life-threatening or disabling. Investment in rare diseases is primarily fueled by increasing recognition of unmet medical needs and the potential for high returns through regulatory incentives, such as orphan drug designation, market exclusivity, and reduced development costs. Such investment supports the development of plasma protease C1-inhibitors by funding research and innovation to address hereditary angioedema and other rare disorders caused by C1-inhibitor deficiencies, thereby accelerating the availability of targeted therapies. For instance, in April 2024, according to Global Genes, a US-based nonprofit organization, companies developing drugs for rare diseases raised $7.1 billion in the first quarter of 2024, a 307% increase compared to $1.8 billion raised in the same period in 2023. Therefore, the growing investment in rare diseases is driving the growth of the plasma protease C1-inhibitor market.

Major companies operating in the plasma protease C1-inhibitor market are focusing on developing innovative solutions, such as recombinant and plasma-derived C1-inhibitors, to prevent and treat hereditary angioedema (HAE) attacks, offering faster symptom relief and improved safety compared with older therapies that had limited availability or slower onset. C1-inhibitors are proteins that regulate the complement system, controlling excessive bradykinin production and reducing the severity of HAE-related swelling episodes. For instance, in January 2023, Takeda Biopharmaceuticals India Private Limited, an India-based pharmaceutical company, launched Cinryze in India, its first approved C1-inhibitor therapy for hereditary angioedema. Cinryze is a plasma-derived C1-inhibitor administered intravenously that replaces deficient or dysfunctional C1-inhibitor protein and helps prevent recurrent HAE attacks; its unique features include high purity, proven efficacy in prophylaxis, and a favorable safety profile. Applications include long-term prophylaxis in adults and adolescents with HAE, with benefits such as reduced frequency and severity of angioedema attacks, improved quality of life, and enhanced access to therapy in India.

In December 2023, Danaher Corporation, a US-based conglomerate, acquired Abcam plc for $5.7 billion. Through this acquisition, Danaher aims to strengthen its life sciences portfolio by enhancing protein research tools and accelerating innovation in disease mapping and drug discovery. Abcam plc is a UK-based biotechnology company that provides several products related to plasma protease C1-inhibitor.

Major companies operating in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Octapharma AG, Ionis Pharmaceuticals Inc, Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc, Pharming Group NV, KalVista Pharmaceuticals Inc, Pharvaris NV, Lev Pharmaceuticals, Shire Pharmaceuticals, Dyax Corp, Intellia Therapeutics Inc, Alnylam Pharmaceuticals Inc, Moderna Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Protalix BioTherapeutics Inc, Apellis Pharmaceuticals Inc, Alexion Pharmaceuticals Inc, UCB SA, Pfizer Inc.

North America was the largest region in the plasma protease C1-inhibitor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protease c1-inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasma protease c1-inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the plasma protease c1-inhibitor market by increasing costs of imported plasma raw materials, recombinant manufacturing inputs, sterile injectables, and cold-chain logistics components. North America and Europe are most affected due to dependence on cross-border plasma sourcing and biologics manufacturing, while Asia-Pacific faces challenges in scaling advanced biologic production. These tariffs are raising therapy prices and influencing supply chain planning. However, they are also encouraging regional plasma collection initiatives, domestic biologics manufacturing, and investment in recombinant technology platforms.

The plasma protease c1-inhibitor market research report is one of a series of new reports that provides plasma protease c1-inhibitor market statistics, including plasma protease c1-inhibitor industry global market size, regional shares, competitors with a plasma protease c1-inhibitor market share, detailed plasma protease c1-inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the plasma protease c1-inhibitor industry. This plasma protease c1-inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plasma protease C1-inhibitors are drugs that inhibit the activity of plasma protease C1 within the complement system. Their primary purpose is to regulate immune responses by preventing excessive complement cascade activation and controlling inflammation. These drugs help maintain balance in immune and coagulation pathways, protecting tissues from damage.

The primary types of drugs that target plasma protease C1-inhibitor include C1-inhibitors, C1-esterase inhibitors, recombinant inhibitors, kallikrein inhibitors, and selective bradykinin B2 receptor antagonists. C1-inhibitors are blood proteins that regulate the complement system, a key component of the immune system responsible for defending against infections and inflammation. These drugs are typically available in lyophilized and injectable dosage forms and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The plasma protease C1-inhibitor market consists of sales of berinert, cinryze, haegarda, firazyr, and lcatibant. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.